Oric Pharmaceuticals (ORIC) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 18, 2026, and will be held virtually, allowing all shareholders to participate regardless of location.

• Shareholders are encouraged to vote via internet, phone, mail, or during the virtual meeting, with the board recommending votes in favor of all proposals.

• The proxy materials and annual report are available online, with efforts to reduce environmental impact through electronic distribution.

Voting matters and shareholder proposals

• Five proposals will be voted on: election of two Class III directors, ratification of KPMG LLP as auditor, approval of the amended 2020 Equity Incentive Plan, advisory approval of executive compensation, and advisory vote on the frequency of future say-on-pay votes.

• The board recommends voting FOR all proposals and for annual (every year) say-on-pay votes.

• Shareholders can submit proposals or director nominations for the 2027 meeting by following specific deadlines and procedures.

Board of directors and corporate governance

• The board consists of six members, five of whom are independent, with staggered three-year terms.

• Jacob M. Chacko, M.D. and Mardi C. Dier are nominated for re-election as Class III directors.

• The board maintains separate roles for chairperson and CEO to reinforce independence.

• Committees include audit, compensation, and nominating/governance, all composed of independent directors.

• Director compensation was updated for 2026 to increase cash and equity awards, aligning with market practices.